PRELIMINARY EVIDENCE SUGGESTING A POTENTIAL BENEFIT OF MEDICATION THERAPY IN MANAGING MASLD IN YOUNG ADULTS WITH OBESITY IN UZBEKISTAN
Keywords:
MASLD, medication therapy, obesity, young adults, UzbekistanAbstract
Metabolic dysfunction-associated steatotic liver disease (MASLD), formerly known as non-alcoholic fatty liver disease (NAFLD), is a growing concern globally, particularly among young adults. This study investigates the potential benefit of medication therapy in managing MASLD in a young population in Uzbekistan. We enrolled 110 patients aged 18-47 years with varying degrees of obesity and MASLD. Our findings suggest that medication therapy, including statins, metformin, and vitamin E, might be associated with improvements in liver function markers and a reduction in liver fat content in this population. However, the specific contribution of each medication to the observed improvements requires further investigation. Further research with larger cohorts and longer follow-up periods is needed to confirm these findings and establish the long-term efficacy and safety of medication therapy in managing MASLD in young adults.
Downloads
References
Go AS, Mozaffarian D, Roger VL, Benjamin EJ, Berry JD, Blaha MJ, et al. Heart disease and stroke statistics−2014 update: a report from the American Heart Association. Circulation. (2014) 129:e28–92. doi: 10.1161/01.cir.0000441139.02102.80
CrossRef Full Text | Google Scholar
Charlton MR, Burns JM, Pedersen RA, Watt KD, Heimbach JK, Dierkhising RA. Frequency and outcomes of liver transplantation for nonalcoholic steatohepatitis in the United States. Gastroenterology. (2011) 141:1249–53. doi: 10.1053/j.gastro.2011.06.061
PubMed Abstract | CrossRef Full Text | Google Scholar
Mathurin P, Bataller R. Trends in the management and burden of alcoholic liver disease. J Hepatol. (2015) 62:S38–46. doi: 10.1016/j.jhep.2015.03.006
PubMed Abstract | CrossRef Full Text | Google Scholar
Younossi ZM, Stepanova M, Afendy M, Fang Y, Younossi Y, Mir H, et al. Changes in the prevalence of the most common causes of chronic liver diseases in the United States from 1988 to 2008. Clin Gastroenterol Hepatol. (2011) 9:524–530.e521; quiz e560. doi: 10.1016/j.cgh.2011.03.020
PubMed Abstract | CrossRef Full Text | Google Scholar
Younossi ZM, Koenig AB, Abdelatif D, Fazel Y, Henry L, Wymer M. Global epidemiology of nonalcoholic fatty liver disease-Meta-analytic assessment of prevalence, incidence, and outcomes. Hepatology. (2016) 64:73–84. doi: 10.1002/hep.28431
PubMed Abstract | Full Text CrossRef | Google Scholar
Radu C, Grigorescu M, Crisan D, Lupsor M, Constantin D, Dina L. Prevalence and associated risk factors of non-alcoholic fatty liver disease in hospitalized patients. J Gastrointestin Liver Dis. (2008) 17:255–60. Available online at: http://www.jgld.ro/2008/3/1.html
PubMed Abstract | Google Scholar
Soderberg C, Stal P, Askling J, Glaumann H, Lindberg G, Marmur J, et al. Decreased survival of subjects with elevated liver function tests during a 28-year follow-up. Hepatology. (2010) 51:595–602. doi: 10.1002/hep.23314
PubMed Abstract | CrossRef Full Text | Google Scholar
Ekstedt M, Hagstrom H, Nasr P, Fredrikson M, Stal P, Kechagias S, et al. Fibrosis stage is the strongest predictor for disease-specific mortality in NAFLD after up to 33 years of follow-up. Hepatology. (2015) 61:1547–54. doi: 10.1002/hep.27368
PubMed Abstract | CrossRef Full Text | Google Scholar
Brinton EA. Effects of ethanol intake on lipoproteins and atherosclerosis. Curr Opin Lipidol. (2010) 21:346–51. doi: 10.1097/MOL.0b013e32833c1f41
PubMed Abstract | CrossRef Full Text | Google Scholar
Sporea I, Popescu A, Dumitrascu D, Brisc C, Nedelcu L, Trifan A, et al. Nonalcoholic fatty liver disease: status quo. J Gastrointestin Liver Dis. (2018) 27:439–48. doi: 10.15403/jgld.2014.1121.274.quo
PubMed Abstract | CrossRef Full Text | Google Scholar
Targher G, Day CP, Bonora E. Risk of cardiovascular disease in patients with nonalcoholic fatty liver disease. N Engl J Med. (2010) 363:1341–50. doi: 10.1056/NEJMra0912063
PubMed Abstract | CrossRef Full Text | Google Scholar
Dumitrascu DL, Neuman MG. Non-alcoholic fatty liver disease: an update on diagnosis. Clujul Med. (2018) 91:147–50. doi: 10.15386/cjmed-993
PubMed Abstract | CrossRef Full Text | Google Scholar
Macavei B, Baban A, Dumitrascu DL. Psychological factors associated with NAFLD/NASH: a systematic review. Eur Rev Med Pharmacol Sci. (2016) 20:5081–97. Available online at: https://www.europeanreview.org/article/11915
PubMed Abstract | Google Scholar
Brunt EM, Janney CG, Dibisceglie AM, Neuschwander-Tetri B, Br B. Nonalcoholic steatohepatitis: a proposal for grading and staging the histological lesions. Am J Gastroenterol. (1999) 9:2476–4.
Google Scholar
Brunt EM. Nonalcoholic steatohepatitis: definition and pathology. Semin Liver Dis. (2001) 21:3–16.
PubMed Abstract | Google Scholar
Chalasani N, Younossi Z. The diagnosis and management of nonalcoholic fatty liver disease: practice guidance from the American Association for the Study of Liver Diseases. (2018) 67:328–57. doi: 10.1002/hep.29367
PubMed Abstract | CrossRef Full Text | Google Scholar
Monsour HP Jr, Frenette CT, Wyne K. Fatty liver: a link to cardiovascular disease–its natural history, pathogenesis, and treatment. Methodist Debakey Cardiovasc J. (2012) 8:21–25.
PubMed Abstract | Google Scholar
Burt Ad RM. Pathology of alcoholic liver disease. In: Bircher J, Benhamou JP, McIntyre N, Rizzetto M, Rodes J, editors. Oxford Textbook of Clinical Hepatology. Oxford: Oxford University Press (1999). pp. 1179–84.
PubMed Abstract
Karl Seitz, H., Mueller, S., and Dancygier, H. Alcoholic liver disease. In: Clinical Hepatology: Principles and Practice of Hepatobiliary Diseases. Berlin; Heidelberg: Springer (2010). pp. 1111–1151. doi: 10.1007/978-3-642-04519-6_34
CrossRef Full Text
Alberti KG, Eckel RH, Grundy SM, Zimmet PZ, Cleeman JI, Donato KA, et al. Harmonizing the metabolic syndrome: a joint interim statement of the International Diabetes Federation Task Force on Epidemiology and Prevention; National Heart, Lung, and Blood Institute; American Heart Association; World Heart Federation; International Atherosclerosis Society; and International Association for the Study of Obesity. Circulation. (2009) 120:1640–5. doi: 10.1161/circulationaha.109.192644
PubMed Abstract | CrossRef Full Text | Google Scholar
Filipović B, Forbes A, Tepeš B, Dumitraşcu DL. Nonalcoholic fatty liver disease. Can J Gastroenterol Hepatol. (2018) 2018:2097435. doi: 10.1155/2018/2097435
CrossRef Full Text | Google Scholar
Kucukazman M, Ata N, Yavuz B, Dal K, Sen O, Deveci OS, et al. Evaluation of early atherosclerosis markers in patients with nonalcoholic fatty liver disease. Eur J Gastroenterol Hepatol. (2013) 25:147–51. doi: 10.1097/MEG.0b013e32835a58b1
PubMed Abstract | CrossRef Full Text | Google Scholar
Gastaldelli A, Kozakova M, Hojlund K, Flyvbjerg A, Favuzzi A, Mitrakou A, et al. Fatty liver is associated with insulin resistance, risk of coronary heart disease, and early atherosclerosis in a large European population. Hepatology. (2009) 49:1537–44. doi: 10.1002/hep.22845
PubMed Abstract | CrossRef Full Text | Google Scholar
Rocha R, Cotrim HP, Carvalho FM, Siqueira AC, Braga H, Freitas LA. Body mass index and waist circumference in non-alcoholic fatty liver disease. J Hum Nutr Diet. (2005) 18:365–70. doi: 10.1111/j.1365-277X.2005.00634.x
PubMed Abstract | CrossRef Full Text | Google Scholar
Lu H, Liu H, Hu F, Zou L, Luo S, Sun L. Independent association between nonalcoholic fatty liver disease and cardiovascular disease: a systematic review and meta-analysis. Int J Endocrinol. (2013) 2013:124958. doi: 10.1155/2013/124958
PubMed Abstract | CrossRef Full Text | Google Scholar
Chitturi S, Abeygunasekera S, Farrell GC, Holmes-Walker J, Hui JM, Fung C, et al. NASH and insulin resistance: insulin hypersecretion and specific association with the insulin resistance syndrome. Hepatology. (2002) 35:373–9. doi: 10.1053/jhep.2002.30692
PubMed Abstract | CrossRef Full Text | Google Scholar
Baliunas DO, Taylor BJ, Irving HEA. Alcohol as a risk factor for type 2 diabetes: a systematic review and meta-analysis. Diabet Care. (2009) 32:2123e2132. doi: 10.2337/dc09-0227
PubMed Abstract | CrossRef Full Text | Google Scholar
Garcia-Compean D, Jaquez-Quintana JO, Gonzalez-Gonzalez JA, Maldonado-Garza H. Liver cirrhosis and diabetes: risk factors, pathophysiology, clinical implications and management. World J Gastroenterol. (2009). 15:280–8. doi: 10.3748/wjg.15.280
PubMed Abstract | CrossRef Full Text
